The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,993,476 in first-year total cost, median $1,415,990.
Most frequent study sections
- Special Emphasis Panel[ZAI1 MFH-M (J1)]5
Most frequent institutions
- ARISAN THERAPEUTICS, INC.1
- NOVOBIOTIC PHARMACEUTICALS, LLC1
- UNIV OF MASSACHUSETTS MED SCH WORCESTER1
- UNIVERSITY OF TEXAS MED BR GALVESTON1
- VENATORX PHARMACEUTICALS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections1R01AI160269-01 | BOYD, STEVEN ARMEN | VENATORX PHARMACEUTICALS, INC., PA | $1,483,227 | ZAI1 |
| 2021 | Developing Teixobactin for Respiratory Infections1R01AI159444-01 | HUGHES, DALLAS | NOVOBIOTIC PHARMACEUTICALS, LLC, MA | $1,469,494 | ZAI1 |
| 2021 | Preclinical development of a vaccine for Nipah virus1R01AI160226-01 | GEISBERT, THOMAS WILLIAM | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $1,415,990 | ZAI1 |
| 2021 | Sialic acid analogs against multidrug-resistant gonorrhea1R01AI160247-01 | MOSS, JOHN ARAM, SANJAY | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $1,316,757 | ZAI1 |
| 2021 | IND-Enabling Studies for Arenavirus Preclinical Candidate1R01AI160246-01 | HENKEL, GREGORY WILLIAM | ARISAN THERAPEUTICS, INC., CA | $1,308,008 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.